Skip to main content

Eptinezumab Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 17, 2022.

For the Consumer

Applies to eptinezumab: intravenous solution

Side effects requiring immediate medical attention

Along with its needed effects, eptinezumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking eptinezumab:

Less common

  • Chest tightness
  • fast heartbeat
  • feeling of warmth
  • fever
  • hives, itching, skin rash
  • hoarseness
  • irritation
  • joint pain, stiffness or swelling
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs
  • redness of the skin
  • redness of the face, neck, arms and occasionally, upper chest
  • swelling of the eyelids, face, lips, hands, or feet
  • trouble breathing or swallowing

Incidence not known

  • Cough
  • dizziness
  • unusual tiredness or weakness

Side effects not requiring immediate medical attention

Some side effects of eptinezumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to eptinezumab: intravenous solution

General

The most commonly reported adverse reactions have been nasopharyngitis and hypersensitivity.[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity

Frequency not reported: Anaphylactic reactions

Hypersensitivity reactions included terms, such as hypersensitivity, pruritus, and flushing/hot flush, occurring on the day of dosing. Hypersensitivity was reported in up to 3% and up to 4% of patients receiving doses of 100 mg or 300 mg, respectively

Respiratory

Common (1% to 10%): Nasopharyngitis

Frequently asked questions

References

1. "Product Information. Vyepti (eptinezumab)." Lundbeck Inc (2020):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.